Latest Headlines
-
Eppendorf Innovation Company Strengthens Access To U.S. Start-Up Scene
2/14/2024
The Eppendorf Innovation Company (EpIC) – a division of Eppendorf SE – continues to expand its international network. Through a targeted investment in Osage University Partners (OUP), EpIC will learn about investment opportunities in some of the most cutting-edge startups transitioning their academic discoveries into the commercial world through OUP’s network of university spinouts.
-
INCOG BioPharma Services Adds 100 Million Units Of Syringe/Cartridge Capacity
2/14/2024
INCOG BioPharma Services, a US-based contract development and manufacturing organization (CDMO) specializing in sterile injectables, is adding a high-speed OPTIMA filling line that will provide an additional 100 million units of syringe and cartridge filling capacity.
-
Analytical Platform LabZientâ„¢, Expedites The Path To IND For Antibodies
2/7/2024
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its new analytical platform, LabZient™. The standardized and automated platform streamlines the assessment and validation of large molecules, which significantly reduces drug development timelines and resource costs.
-
Waisman Biomanufacturing & RoosterBio Announce Collaboration For GMP Manufacturing of Cell & Exosome Therapies
2/6/2024
Waisman Biomanufacturing, a leading contract development and manufacturing organization (CDMO) which is strategically part of the University of Wisconsin Madison, announced today a strategic partnership with RoosterBio, Inc., a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services.
-
Purolite And Repligen Announce The Commercial Launch Of A Novel CH1 Affinity Resin For The Purification Of Specialized mAbs
2/6/2024
Purolite, an Ecolab company and leading manufacturer of synthetic and agarose-based bioprocessing resins, and Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of Praesto® CH1, a new 70μm (micron) agarose-based affinity resin designed to purify specialized mAbs such as bispecifics and recombinant antibody fragments.
-
Novo Holdings To Acquire CDMO Catalent Pharma Solutions For $16.5 Billion
2/5/2024
Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, today announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.
-
Solesis, Parent Company of Charter Medical, to Expand Single-use Manufacturing Capabilities into Costa Rica
2/2/2024
The site will expand capabilities to enable development in the fast-growing cardiovascular and advanced therapy markets.
-
Cleanroom Leader AES Clean Technology Announces New Vice President Of Construction
2/1/2024
A leading provider of high-performance cleanroom facilities, AES Clean Technology, has announced the appointment of John Costalas to its senior leadership team as Vice President of Construction.
-
AustinPx Partners With Microsize On KinetiSol® Technology
1/31/2024
AustinPx, a contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement of orally delivered small molecule drug candidates, and Microsize, a leading active pharmaceutical ingredient enhancement CDMO, today announced the strategic partnership to accelerate the commercial application of AustinPx’s KinetiSol® Technology platform. The collaboration will enable AustinPx’s clients to manufacture their late-phase clinical and commercial KinetiSol drug product intermediate at Microsize’s purpose built, FDA-inspected facility.
-
AbbVie Announces $223 Million Investment For New Biologics Manufacturing Facility In Singapore
1/29/2024
AbbVie (NYSE: ABBV) strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million (S$301 million) expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie's global network.